Novel therapeutic approaches (including gene therapy)

PE66

VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IPROTECT1 multicenter European study

Katlama C.1, Rockstroh J.K.2, Gatell J.M.3, Ho Tsong Fang R.4, Girard P.M.5, Slama L.6, Simon A.7, Launay O.8, Cotte L.9, Reynes J.10, Gharakhanian S.11

1AP-HP Pitie Salpetriere Hospital & INSERM, Paris, France, 2University of Bonn, Bonn, Germany, 3Hospital Clinic, Barcelona, Spain, 4InnaVirVax, Genopole Evry, France, 5AP-HP St Antoine Hospital, Paris, France, 6AP-HP Tenon Hospital, Paris, France, 7AP-HP Pitie-Salpetriere Hospital, Paris, France, 8AP-HP Cochin-Pasteur & INSERM CIC, Paris, France, 9Croix Rousse Hospital, Lyon, France, 10University Hospital, Montpellier, France, 11Cambridge Innovation Center, InnaVirVax, Cambridge, United States

Background: VAC-3S is a novel vaccine directed to the highly conserved gp41, 3S motif of HIV-1. Anti-3S antibodies (Abs) block 3S binding to gC1qR, prevents CD4 surface expression of NKp44L, the natural ligand of NKp44 expressed on activated Natural Killer cells. Anti-3S Abs have anti-CD4 apoptotic effects, in vitro. High 3S Abs are associated with low inflammation biomarkers in SHIV-infected macaques. Anti-3S Abs have been shown to be negatively correlated with HIV DNA. We hypothesize that VAC-3S enables re-establishment of CD4/CD8 homeostasis hence can comprise the immunological component of an HIV functional cure approach.

Methods: Prospective, randomized, placebo-controlled, double-blind, 3-step study in Europe, assessing immunotherapeutic properties of VAC-3S at 16, 32, 64 mg with 3 IM base immunizations at 4 wk intervals and 3 maintenance boosters in the 16, 32 mg arms. Ninety HIV ART suppressed pts with 200-350 & 350-500 CD4 c/mm3 planned. Endpoints include: anti-3S Abs (ELISA), T lymphocyte activation/differentiation, HIV DNA, inflammatory biomarkers. Planned analysis after 50% inclusions in first 2-steps.

Results: In these first two steps, 56 pts (47 male / 9 female), randomized, and completed vaccinations. Pts are 62% Caucasian, 30% African heritage. Median age 46 years (23-59); BMI 23 kg/m2 (16-33), HIV duration 60 months (1-346); baseline CD4 count 365 cells/mm3 (200-596); nadir CD4 167 cells/mm3 (31-410). One serious Adverse Event (AE) prior to vaccination, one viral rebound post-ART non-adherence. One hundred twenty AEs reported after a total 182 vaccinations, were local (erythema, induration, sensitivity, pain), or systemic (headache, myalgia, vertigo). AEs were mild in 53% pts, moderate in 39% pts, severe in 6% pts. Figure 1 shows immunogenicity. Median CD4/CD8 ratios, at baseline, were 0.48 (0.20-1.46) and 0.66 (0.23-2.90) in the low and high CD4 strata, respectively. At the 12-weeks post-vaccination point CD4/CD8 ratio was 0.49 (0.21-1.120) in the low and 0.57 (0.34-2.82) in the high CD4 strata.
Conclusions: VAC-3S is a novel mechanism immunotherapeutic HIV vaccine. Phase II preliminary results, confirms phase I safety, as well as, immunogenicity for all new dose levels assessed. Scheduled long term evaluation includes CD4/CD8 homeostasis, HIV DNA and biomarkers of chronic inflammation.